Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1000

1.

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation.

Fox KAA, Velentgas P, Camm AJ, Bassand JP, Fitzmaurice DA, Gersh BJ, Goldhaber SZ, Goto S, Haas S, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Dabrowski E, Luo K, Gibbs L, Kakkar AK; GARFIELD-AF Investigators.

JAMA Netw Open. 2020 Feb 5;3(2):e200107. doi: 10.1001/jamanetworkopen.2020.0107.

PMID:
32101311
2.

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban.

Kirchhof P, Haas S, Amarenco P, Hess S, Lambelet M, van Eickels M, Turpie AGG, Camm AJ; XANTUS Investigators*.

J Am Heart Assoc. 2020 Mar 3;9(5):e009530. doi: 10.1161/JAHA.118.009530. Epub 2020 Feb 21.

3.

Development of an international standard set of outcome measures for patients with atrial fibrillation: a report of the International Consortium for Health Outcomes Measurement (ICHOM) atrial fibrillation working group.

Seligman WH, Das-Gupta Z, Jobi-Odeneye AO, Arbelo E, Banerjee A, Bollmann A, Caffrey-Armstrong B, Cehic DA, Corbalan R, Collins M, Dandamudi G, Dorairaj P, Fay M, Van Gelder IC, Goto S, Granger CB, Gyorgy B, Healey JS, Hendriks JM, Hills MT, Hobbs FDR, Huisman MV, Koplan KE, Lane DA, Lewis WR, Lobban T, Steinberg BA, McLeod CJ, Moseley S, Timmis A, Yutao G, Camm AJ.

Eur Heart J. 2020 Jan 29. pii: ehz871. doi: 10.1093/eurheartj/ehz871. [Epub ahead of print]

PMID:
31995195
4.

Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial.

Kirchhof P, Ezekowitz MD, Purmah Y, Schiffer S, Meng IL, Camm AJ, Hohnloser SH, Schulz A, Wosnitza M, Cappato R.

TH Open. 2020 Jan 23;4(1):e20-e32. doi: 10.1055/s-0040-1701206. eCollection 2020 Jan.

5.

The year in cardiology: arrhythmias and pacing.

Camm AJ, Lip GYH, Schilling R, Calkins H, Steffel J.

Eur Heart J. 2020 Feb 1;41(5):619-625c. doi: 10.1093/eurheartj/ehz931. No abstract available.

PMID:
31901935
6.

Prior stroke and transient ischemic attack as risk factors for subsequent stroke in atrial fibrillation patients: A report from the GARFIELD-AF registry.

Hacke W, Bassand JP, Virdone S, Camm AJ, Fitzmaurice DA, Fox KA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AG, van Eickels M, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators.

Int J Stroke. 2019 Dec 17:1747493019891516. doi: 10.1177/1747493019891516. [Epub ahead of print]

PMID:
31847794
7.

New AI Prediction Model Using Serial PT-INR Measurements in AF Patients on VKAs: GARFIELD-AF.

Goto S, Goto S, Pieper KS, Bassand JP, Camm AJ, Fitzmaurice DA, Goldhaber SZ, Haas S, Parkhomenko A, Oto A, Misselwitz F, Turpie AGG, Verheugt FWA, Fox KAA, Gersh BJ, Kakkar AK; GARFIELD-AF Investigators.

Eur Heart J Cardiovasc Pharmacother. 2019 Dec 10. pii: pvz076. doi: 10.1093/ehjcvp/pvz076. [Epub ahead of print]

PMID:
31821482
8.

Impact of oral anticoagulation in patients with atrial fibrillation at very low thromboembolic risk.

Verbrugge FH, Martin AC, Siegal D, Pieper K, Illingworth L, Camm AJ, Fox KAA.

Heart. 2019 Dec 5. pii: heartjnl-2019-315873. doi: 10.1136/heartjnl-2019-315873. [Epub ahead of print]

PMID:
31806700
9.

Do Data Derived From Registries Help or Confuse the Assessment of Left Atrial Appendage Closure?

Camm AJ.

J Am Coll Cardiol. 2019 Dec 10;74(23):2890-2892. doi: 10.1016/j.jacc.2019.10.025. No abstract available.

PMID:
31806132
10.

The association between patterns of atrial fibrillation, anticoagulation, and cardiovascular events.

Atar D, Berge E, Le Heuzey JY, Virdone S, Camm AJ, Steffel J, Gibbs H, Goldhaber SZ, Goto S, Kayani G, Misselwitz F, Stepinska J, Turpie AGG, Bassand JP, Kakkar AK; GARFIELD-AF Investigators.

Europace. 2020 Feb 1;22(2):195-204. doi: 10.1093/europace/euz292.

11.

GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study.

Dalgaard F, Pieper K, Verheugt F, Camm AJ, Fox KA, Kakkar AK, Pallisgaard JL, Rasmussen PV, Weert HV, Lindhardt TB, Torp-Pedersen C, Gislason GH, Ruwald MH, Harskamp RE.

BMJ Open. 2019 Nov 11;9(11):e033283. doi: 10.1136/bmjopen-2019-033283.

12.

A New Biomarker in Atrial Fibrillation: Monocyte Chemoattractant Protein-1-Induced Protein.

Savelieva I, Camm AJ.

Cardiology. 2019;144(3-4):122-124. doi: 10.1159/000502253. Epub 2019 Nov 12. No abstract available.

PMID:
31715611
13.

Impact of stable angina on health status and quality of life perception of currently treated patients. The BRIDGE 2 survey.

Manolis AJ, Ambrosio G, Collins P, Dechend R, Lopez-Sendon J, Pegoraro V, Camm AJ.

Eur J Intern Med. 2019 Dec;70:60-67. doi: 10.1016/j.ejim.2019.09.013. Epub 2019 Nov 5.

14.

Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week.

Kumar S, Lim E, Covic A, Verhamme P, Gale CP, Camm AJ, Goldsmith D.

J Am Coll Cardiol. 2019 Oct 29;74(17):2204-2215. doi: 10.1016/j.jacc.2019.08.1031. Review.

PMID:
31648714
15.

Cardiovascular care of patients with stroke and high risk of stroke: The need for interdisciplinary action: A consensus report from the European Society of Cardiology Cardiovascular Round Table.

Doehner W, Mazighi M, Hofmann BM, Lautsch D, Hindricks G, Bohula EA, Byrne RA, Camm AJ, Casadei B, Caso V, Cognard C, Diener HC, Endres M, Goldstein P, Halliday A, Hopewell JC, Jovanovic DR, Kobayashi A, Kostrubiec M, Krajina A, Landmesser U, Markus HS, Ntaios G, Pezzella FR, Ribo M, Rosano GM, Rubiera M, Sharma M, Touyz RM, Widimsky P.

Eur J Prev Cardiol. 2019 Sep 30:2047487319873460. doi: 10.1177/2047487319873460. [Epub ahead of print]

PMID:
31569966
16.

The Thrombosis Research Institute, London.

Kakkar AK, Camm AJ, Fox KAA.

Eur Heart J. 2019 Jul 14;40(27):2184-2186. doi: 10.1093/eurheartj/ehz494. No abstract available.

PMID:
31505614
17.

EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update.

Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GYH, Fauchier L, Betts TR, Lewalter T, Saw J, Tzikas A, Sternik L, Nietlispach F, Berti S, Sievert H, Bertog S, Meier B; ESC Scientific Document Group .

Europace. 2019 Aug 31. pii: euz258. doi: 10.1093/europace/euz258. [Epub ahead of print] No abstract available.

PMID:
31504441
18.

EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update.

Glikson M, Wolff R, Hindricks G, Mandrola J, Camm AJ, Lip GYH, Fauchier L, Betts TR, Lewalter T, Saw J, Tzikas A, Sternik L, Nietlispach F, Berti S, Sievert H, Bertog S, Meier B.

EuroIntervention. 2020 Jan 17;15(13):1133-1180. doi: 10.4244/EIJY19M08_01. No abstract available.

19.

Clinical utility of magnetocardiography in cardiology for the detection of myocardial ischemia.

Camm AJ, Henderson R, Brisinda D, Body R, Charles RG, Varcoe B, Fenici R.

J Electrocardiol. 2019 Nov - Dec;57:10-17. doi: 10.1016/j.jelectrocard.2019.07.009. Epub 2019 Jul 25. Review. No abstract available.

PMID:
31442563
20.

RE-CIRCUIT: uninterrupted anticoagulation with dabigatran to cover left atrial ablation procedures.

Camm AJ.

Cardiovasc Res. 2018 Oct 1;114(12):e89-e90. doi: 10.1093/cvr/cvy204. No abstract available.

PMID:
31346598
21.

Safety and efficacy of dronedarone from clinical trials to real-world evidence: implications for its use in atrial fibrillation.

Boriani G, Blomström-Lundqvist C, Hohnloser SH, Bergfeldt L, Botto GL, Capucci A, Lozano IF, Goette A, Israel CW, Merino JL, Camm AJ.

Europace. 2019 Jul 19. pii: euz193. doi: 10.1093/europace/euz193. [Epub ahead of print]

PMID:
31324921
22.

Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF.

Verheugt FWA, Ambrosio G, Atar D, Bassand JP, Camm AJ, Costabel JP, Fitzmaurice DA, Illingworth L, Goldhaber SZ, Goto S, Haas S, Jansky P, Kayani G, Stepinska J, Turpie AGG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators.

Am J Med. 2019 Dec;132(12):1431-1440.e7. doi: 10.1016/j.amjmed.2019.06.008. Epub 2019 Jul 12.

PMID:
31306621
23.

The New CHEST Guidelines on Antithrombotic Therapy for Atrial Fibrillation Should Consider Recent Data on Rivaroxaban.

Kim YH, Shim J, Tsai CT, Wang CC, Vilela G, Muengtaweepongsa S, Kurniawan M, Maskon O, Hsu LF, Nguyen TH, Sim K, Camm AJ.

Chest. 2019 Jun;155(6):1309-1311. doi: 10.1016/j.chest.2019.03.036. No abstract available.

PMID:
31174652
24.

International longitudinal registry of patients with atrial fibrillation and treated with rivaroxaban: RIVaroxaban Evaluation in Real life setting (RIVER).

Beyer-Westendorf J, Camm AJ, Fox KAA, Le Heuzey JY, Haas S, Turpie AGG, Virdone S, Kakkar AK; RIVER Registry Investigators.

Thromb J. 2019 Apr 25;17:7. doi: 10.1186/s12959-019-0195-7. eCollection 2019.

25.

Predictors of NOAC versus VKA use for stroke prevention in patients with newly diagnosed atrial fibrillation: Results from GARFIELD-AF.

Haas S, Camm AJ, Bassand JP, Angchaisuksiri P, Cools F, Corbalan R, Gibbs H, Jacobson B, Koretsune Y, Mantovani LG, Misselwitz F, Panchenko E, Ragy HI, Stepinska J, Turpie AG, Sawhney JP, Steffel J, Lim TW, Pieper KS, Virdone S, Verheugt FW, Kakkar AK; GARFIELD-AF Investigators.

Am Heart J. 2019 Jul;213:35-46. doi: 10.1016/j.ahj.2019.03.013. Epub 2019 Apr 11.

26.

Analysis of Outcomes in Ischemic vs Nonischemic Cardiomyopathy in Patients With Atrial Fibrillation: A Report From the GARFIELD-AF Registry.

Corbalan R, Bassand JP, Illingworth L, Ambrosio G, Camm AJ, Fitzmaurice DA, Fox KAA, Goldhaber SZ, Goto S, Haas S, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, Verheugt FWA, Kakkar AK; GARFIELD-AF Investigators.

JAMA Cardiol. 2019 Jun 1;4(6):526-548. doi: 10.1001/jamacardio.2018.4729.

PMID:
31066873
27.

EHRA White Paper: knowledge gaps in arrhythmia management-status 2019.

Goette A, Auricchio A, Boriani G, Braunschweig F, Terradellas JB, Burri H, Camm AJ, Crijns H, Dagres N, Deharo JC, Dobrev D, Hatala R, Hindricks G, Hohnloser SH, Leclercq C, Lewalter T, Lip GYH, Merino JL, Mont L, Prinzen F, Proclemer A, Pürerfellner H, Savelieva I, Schilling R, Steffel J, van Gelder IC, Zeppenfeld K, Zupan I, Heidbüchel H; ESC Scientific Document Group .

Europace. 2019 Jul 1;21(7):993-994. doi: 10.1093/europace/euz055.

PMID:
30882143
28.

Left atrial ablation for management of atrial fibrillation: CABANA vs. real-world data. Apples and oranges?

Camm AJ.

Eur Heart J. 2019 Apr 21;40(16):1265-1267. doi: 10.1093/eurheartj/ehz168. No abstract available.

PMID:
30875420
29.

Management and 1-Year Outcomes of Patients With Newly Diagnosed Atrial Fibrillation and Chronic Kidney Disease: Results From the Prospective GARFIELD - AF Registry.

Goto S, Angchaisuksiri P, Bassand JP, Camm AJ, Dominguez H, Illingworth L, Gibbs H, Goldhaber SZ, Goto S, Jing ZC, Haas S, Kayani G, Koretsune Y, Lim TW, Oh S, Sawhney JPS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK; GARFIELD‐AF Investigators.

J Am Heart Assoc. 2019 Feb 5;8(3):e010510. doi: 10.1161/JAHA.118.010510.

30.

The Cardiovascular Effects of a Meal: J-Tpeak and Tpeak -Tend Assessment and Further Insights Into the Physiological Effects.

Täubel J, Ferber G, Van Langenhoven L, Del Bianco T, Fernandes S, Djumanov D, Kanters JK, Graff C, Camm AJ.

J Clin Pharmacol. 2019 Jun;59(6):799-810. doi: 10.1002/jcph.1374. Epub 2019 Jan 11.

31.

Early Risks of Death, Stroke/Systemic Embolism, and Major Bleeding in Patients With Newly Diagnosed Atrial Fibrillation.

Bassand JP, Virdone S, Goldhaber SZ, Camm AJ, Fitzmaurice DA, Fox KAA, Goto S, Haas S, Hacke W, Kayani G, Mantovani LG, Misselwitz F, Pieper KS, Turpie AGG, van Eickels M, Verheugt FWA, Kakkar AK.

Circulation. 2019 Feb 5;139(6):787-798. doi: 10.1161/CIRCULATIONAHA.118.035012.

PMID:
30586740
32.

Atrial fibrillation: the era of scientific breakthrough.

Hindricks G, Savelieva I, Camm AJ.

Europace. 2018 Nov 1;20(FI_3):f275-f277. doi: 10.1093/europace/euy279. No abstract available.

PMID:
30481316
33.

Reply: Anticoagulants for Cardioembolism Prevention in Atrial Fibrillation Patients: Potential Bias From Real-World Studies.

Kirchhof P, Bach M, Camm AJ.

J Am Coll Cardiol. 2018 Nov 13;72(20):2546-2547. doi: 10.1016/j.jacc.2018.09.024. No abstract available.

34.

Outcomes associated with non-recommended dosing of rivaroxaban: results from the XANTUS study.

Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG, Camm AJ.

Eur Heart J Cardiovasc Pharmacother. 2019 Apr 1;5(2):70-79. doi: 10.1093/ehjcvp/pvy041.

PMID:
30423165
35.

[The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary].

Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H.

Kardiol Pol. 2018;76(9):1283-1298. doi: 10.5603/KP.2018.0180. Polish.

36.

XANAP: A real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia.

Kim YH, Shim J, Tsai CT, Wang CC, Vilela G, Muengtaweepongsa S, Kurniawan M, Maskon O, Li Fern H, Nguyen TH, Thanachartwet T, Sim K, Camm AJ; XANAP investigators.

J Arrhythm. 2018 Jul 6;34(4):418-427. doi: 10.1002/joa3.12073. eCollection 2018 Aug.

37.

Sta Ble Angina: Pe Rcept Ion of Nee Ds, Quality of Life and Mana Gem Ent of Patients (BRIDGE Study)-A Multinational European Physician Survey.

Ambrosio G, Collins P, Dechend R, Lopez-Sendon J, Manolis AJ, Camm AJ.

Angiology. 2019 May;70(5):397-406. doi: 10.1177/0003319718796313. Epub 2018 Aug 27.

PMID:
30149731
38.

Real-world vs. randomized trial outcomes in similar populations of rivaroxaban-treated patients with non-valvular atrial fibrillation in ROCKET AF and XANTUS.

Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Lambelet M, Bach M, Turpie AGG.

Europace. 2019 Mar 1;21(3):421-427. doi: 10.1093/europace/euy160.

PMID:
30052894
39.

A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation.

Camm AJ, Dorian P, Hohnloser SH, Kowey PR, Tyl B, Ni Y, Vandzhura V, Maison-Blanche P, de Melis M, Sanders P.

Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):21-28. doi: 10.1093/ehjcvp/pvy022.

PMID:
30052825
40.

Diurnal Profile of the QTc Interval Following Moxifloxacin Administration.

Täubel J, Ferber G, Fernandes S, Camm AJ.

J Clin Pharmacol. 2019 Jan;59(1):35-44. doi: 10.1002/jcph.1283. Epub 2018 Jul 24.

PMID:
30040135
41.

Global Prospective Safety Analysis of Rivaroxaban.

Kirchhof P, Radaideh G, Kim YH, Lanas F, Haas S, Amarenco P, Turpie AGG, Bach M, Lambelet M, Hess S, Camm AJ; Global XANTUS program Investigators.

J Am Coll Cardiol. 2018 Jul 10;72(2):141-153. doi: 10.1016/j.jacc.2018.04.058.

42.

Effect of Systemic Hypertension With Versus Without Left Ventricular Hypertrophy on the Progression of Atrial Fibrillation (from the Euro Heart Survey).

Erküner Ö, Dudink EAMP, Nieuwlaat R, Rienstra M, Van Gelder IC, Camm AJ, Capucci A, Breithardt G, LeHeuzey JY, Lip GYH, Crijns HJGM, Luermans JGLM.

Am J Cardiol. 2018 Aug 15;122(4):578-583. doi: 10.1016/j.amjcard.2018.04.053. Epub 2018 May 11.

43.

Strengths and weaknesses of 'real-world' studies involving non-vitamin K antagonist oral anticoagulants.

Camm AJ, Fox KAA.

Open Heart. 2018 Apr 21;5(1):e000788. doi: 10.1136/openhrt-2018-000788. eCollection 2018. Review.

44.

Oral anticoagulant use in cardiovascular disorders: a perspective on present and potential indications for rivaroxaban.

Camm AJ, Fox KAA.

Curr Med Res Opin. 2018 Nov;34(11):1945-1957. doi: 10.1080/03007995.2018.1467885. Epub 2018 May 21. Review.

PMID:
29672182
45.

Time trends in antithrombotic management of patients with atrial fibrillation treated with coronary stents: Results from TALENT-AF (The internAtionaL stENT - Atrial Fibrillation study) multicenter registry.

Potter BJ, Andò G, Cimmino G, Ladeiras-Lopes R, Frikah Z, Chen XY, Virga V, Goncalves-Almeida J, Camm AJ, Fox KAA.

Clin Cardiol. 2018 Apr;41(4):470-475. doi: 10.1002/clc.22898. Epub 2018 Apr 17.

46.

State of play and future direction with NOACs: An expert consensus.

Cohen AT, Lip GY, De Caterina R, Heidbuchel H, Zamorano JL, Agnelli G, Verheugt F, Camm AJ.

Vascul Pharmacol. 2018 Jul;106:9-21. doi: 10.1016/j.vph.2018.04.001. Epub 2018 Apr 12. Review.

PMID:
29656119
47.

The Rivaroxaban Program and the Management of Unmet Needs in Thromboembolic Disease.

Camm AJ.

Thromb Haemost. 2018 May;118(S 01):S2-S11. doi: 10.1055/s-0038-1632387. Epub 2018 Mar 22. Review.

PMID:
29566415
48.

Understanding the Value of Real-World Evidence: Focus on Stroke Prevention in Atrial Fibrillation with Rivaroxaban.

Camm AJ, Coleman CI, Larsen TB, Nielsen PB, Tamayo CS.

Thromb Haemost. 2018 May;118(S 01):S45-S60. doi: 10.1055/s-0038-1635084. Epub 2018 Mar 22.

PMID:
29566414
49.

The Evolution of Antithrombotic Care in Cardiovascular Patients.

Camm AJ.

Thromb Haemost. 2018 May;118(S 01):S1. doi: 10.1055/s-0038-1626720. Epub 2018 Mar 22. No abstract available.

PMID:
29566412
50.

The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.

Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Georg Haeusler K, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group.

Europace. 2018 Aug 1;20(8):1231-1242. doi: 10.1093/europace/euy054. Review.

PMID:
29562331

Supplemental Content

Support Center